Paper39478665
Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition.
Li X and 1 other. J Med Chem, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition. Papers, record 39478665. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39478665
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Perspective for Drug Discovery Targeting SARS Coronavirus Methyltransferases: Function, Structure and Inhibition.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Methyltransferases | Major topic |
| Antiviral Agents | Major topic |
| Drug Discovery | Major topic |
| SARS-CoV-2 | Major topic |
| Severe acute respiratory syndrome-related coronavirus | Major topic |
| Humans | |
| COVID-19 Drug Treatment | |
| COVID-19 | |
| Enzyme Inhibitors | |
| Viral Nonstructural Proteins |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA266057 | NCI NIH HHS | United States | R01CA266057 | PubMed | NIH RePORTER |
| R21 AI159323 | NIAID NIH HHS | United States | R21AI159323 | PubMed | NIH RePORTER |
| RP220232 | NIH | PubMed | PubMed |
References118
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36546776 | Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal details of exoribonuclease activation and mRNA capping and provide starting points for antiviral drug development. | Nucleic Acids Res | 2023 | https://conductscience.org/library/papers/36546776 | PubMed |
| 2 | 33724070 | Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry. | SLAS Discov | 2021 | https://conductscience.org/library/papers/33724070 | PubMed |
| 3 | 25626080 | RNA methyltransferases involved in 5' cap biosynthesis. | RNA Biol | 2014 | https://conductscience.org/library/papers/25626080 | PubMed |
| 4 | 37659195 | Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review. | Eur J Med Chem | 2023 | https://conductscience.org/library/papers/37659195 | PubMed |
| 5 | 34845015 | Structure-function analysis of the nsp14 N7-guanine methyltransferase reveals an essential role in Betacoronavirus replication. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34845015 | PubMed |
| 6 | 34641339 | Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. | Molecules | 2021 | https://conductscience.org/library/papers/34641339 | PubMed |
| 7 | 32075877 | Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. | Science | 2020 | https://conductscience.org/library/papers/32075877 | PubMed |
| 8 | 32259329 | Direct High-Throughput Screening Assay for mRNA Cap Guanine-N7 Methyltransferase Activity. | Chemistry | 2020 | https://conductscience.org/library/papers/32259329 | PubMed |
| 9 | 15629030 | Complete genome sequences of the SARS-CoV: the BJ Group (Isolates BJ01-BJ04). | Genomics Proteomics Bioinformatics | 2003 | https://conductscience.org/library/papers/15629030 | PubMed |
| 10 | 36764586 | SS148 and WZ16 inhibit the activities of nsp10-nsp16 complexes from all seven human pathogenic coronaviruses. | Biochim Biophys Acta Gen Subj | 2023 | https://conductscience.org/library/papers/36764586 | PubMed |
| 11 | 37683636 | Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with SARS-CoV-2. | Med | 2023 | https://conductscience.org/library/papers/37683636 | PubMed |
| 12 | 32201080 | Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection. | Biochem Biophys Res Commun | 2020 | https://conductscience.org/library/papers/32201080 | PubMed |
| 13 | 32439197 | COVID-19 and Multiorgan Response. | Curr Probl Cardiol | 2020 | https://conductscience.org/library/papers/32439197 | PubMed |
| 14 | 12690092 | A novel coronavirus associated with severe acute respiratory syndrome. | N Engl J Med | 2003 | https://conductscience.org/library/papers/12690092 | PubMed |
| 15 | 18255185 | The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein. | Virus Res | 2008 | https://conductscience.org/library/papers/18255185 | PubMed |
| 16 | 35439007 | Potent Inhibition of SARS-CoV-2 nsp14 N7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues. | J Med Chem | 2022 | https://conductscience.org/library/papers/35439007 | PubMed |
| 17 | 34131072 | Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16. | Sci Signal | 2021 | https://conductscience.org/library/papers/34131072 | PubMed |
| 18 | 36075969 | High-resolution structures of the SARS-CoV-2 N7-methyltransferase inform therapeutic development. | Nat Struct Mol Biol | 2022 | https://conductscience.org/library/papers/36075969 | PubMed |
| 19 | 32563813 | Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase. | Eur J Med Chem | 2020 | https://conductscience.org/library/papers/32563813 | PubMed |
| 20 | 31986257 | A novel coronavirus outbreak of global health concern. | Lancet | 2020 | https://conductscience.org/library/papers/31986257 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42921030 | Structure-Based Design of New Nonpeptidic Covalent Mpro Inhibitors against SARS-CoV‑2 and Omicron Variants. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42921030 | PubMed |
| 42123558 | From Epigenetic Regulation to Protein Degradation: Emerging Strategies for Anti-Infective Drug Discovery. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123558 | PubMed |
| 41337461 | Moringa oleifera potential for the treatment and prevention of COVID-19 involving molecular interaction, antioxidant properties and kinetic mechanism. | PLoS One | 2025 | https://conductscience.org/library/papers/41337461 | PubMed |
| 41184286 | SARS-CoV-2 NSP14 inhibitor exhibits potent antiviral activity and reverses NSP14-driven host modulation. | Nat Commun | 2025 | https://conductscience.org/library/papers/41184286 | PubMed |
| 40910582 | Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors. | J Med Chem | 2025 | https://conductscience.org/library/papers/40910582 | PubMed |
| 40143346 | Structural Virology: The Key Determinants in Development of Antiviral Therapeutics. | Viruses | 2025 | https://conductscience.org/library/papers/40143346 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39478665
GET https://conductscience.org/api/papers/v1/39478665/references?page=2